The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers.
Colon cancer
Prognosis
RAS mutation
Recurrence pattern
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
16 May 2023
16 May 2023
Historique:
accepted:
07
05
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
aheadofprint
Résumé
It is known that the RAS and BRAF mutations are predictive for targeted therapies in treating metastatic colon cancer and negatively affect the prognosis of the disease. However, there are limited studies in early-stage colon cancer about the relationship of this mutational condition with the prognosis and relapse pattern of the disease. In this study, we evaluated the effects of mutational status on the clinical pattern of recurrence and survival in early-stage colon cancer in addition to classical risk factors. Patients with early-stage colon cancer at the first time of diagnosis and developing recurrence or metastasis on following up were included in this study. Patients were divided into two groups according to the at the time of relapse RAS/BRAF mutation status: mutant or non-mutant/wild types. Then, mutation analysis was performed again from the early-stage tissue of the patients if available. The relationship between early-stage mutation status and progression-free survival (PFS), overall survival (OS), and relapse pattern was analyzed. The number of patients with mutant and non-mutations in the early stage was 39 and 40, respectively. Mutant and non-mutant patients with stage 3 disease were similar (69% and 70%, respectively). OS (47.27 months vs. 67.53 months; p = 0.02) and PFS (25.12 vs. 38.13 months; p = 0.049) were statistically significantly lower in mutant patients, respectively. Most patients had distant metastases on both sides at recurrence (61.5% vs. 62.5%, respectively). There was no significant difference between mutant and non-mutant patients regarding distant metastasis and local recurrence rates (p = 0.657). A discordance of 11.4% between early-stage and late-stage tissue mutation status. The presence of mutation in early-stage colon cancer is associated with shorter OS and PFS. The mutational status did not have a significant effect on the recurrence pattern. Because of the discordance of early-stage and late-stage mutational status, it is recommended to perform mutation analysis from tissue at relapse.
Identifiants
pubmed: 37191843
doi: 10.1007/s12029-023-00943-2
pii: 10.1007/s12029-023-00943-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Arnold M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
doi: 10.1136/gutjnl-2015-310912
pubmed: 26818619
Vogelstein B, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32.
doi: 10.1056/NEJM198809013190901
pubmed: 2841597
Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059–72.
doi: 10.1053/j.gastro.2009.12.065
pubmed: 20420946
Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–99.
doi: 10.1053/j.gastro.2008.07.076
pubmed: 18773902
Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.
doi: 10.1056/NEJMoa033025
pubmed: 15269313
Lièvre A, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.
doi: 10.1158/0008-5472.CAN-06-0191
pubmed: 16618717
Laurent-Puig P, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924–30.
doi: 10.1200/JCO.2008.21.6796
pubmed: 19884556
Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374–9.
doi: 10.1200/JCO.2007.12.5906
pubmed: 18202412
Bruzzi M, et al. Influence of molecular status on recurrence site in patients treated for a stage III colon cancer: a post hoc analysis of the PETACC-8 trial. Ann Surg Oncol. 2019;26(11):3561–7.
doi: 10.1245/s10434-019-07513-6
pubmed: 31209667
Yoon HH, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20(11):3033–43.
doi: 10.1158/1078-0432.CCR-13-3140
pubmed: 24687927
pmcid: 4040326
Kadowaki S, et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 2015;21(4):1275–83.
doi: 10.3748/wjg.v21.i4.1275
pubmed: 25632202
pmcid: 4306173
Smeby J, et al. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol. 2018;29(5):1227–34.
doi: 10.1093/annonc/mdy085
pubmed: 29518181
pmcid: 5961317
Domingo E, et al. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol. 2018;3(9):635–43.
doi: 10.1016/S2468-1253(18)30117-1
pubmed: 30042065
pmcid: 6088509
Taieb J, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol. 2016;2(5):643–53.
doi: 10.1001/jamaoncol.2015.5225
pubmed: 26768652
Taieb J, et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst. 2017;109(5).
Birgisson H, et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer. 2015;15:125.
doi: 10.1186/s12885-015-1144-x
pubmed: 25884297
pmcid: 4364587
Tie J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17(5):1122–30.
doi: 10.1158/1078-0432.CCR-10-1720
pubmed: 21239505
Tran B, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–32.
doi: 10.1002/cncr.26086
pubmed: 21456008
Prasanna T, et al. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncol. 2018;57(11):1438–44.
doi: 10.1080/0284186X.2018.1487581
pubmed: 30035653
Yong ZZ, Ching GTH, Ching MTC. Metastatic profile of colorectal cancer: interplay between primary tumor location and KRAS status. J Surg Res. 2020;246:325–34.
doi: 10.1016/j.jss.2018.11.025